3D Medicines Inc

3D Medicines Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products in the People's Republic of China. Its lead product, Envafolimab, is a subcutaneous PD-L1 antibody approved for previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors. The company is also developing Envafolimab in Phase III trials for advanced BTC, NSCLC, and TMB-H advanced cancer, and in Phase II trials for G/GEJ, EC, HCC, CRC, NSCLC, microsatellite stable CRC, and dMMR advanced solid tumors. Its pipeline includes 3D189, 3D229 (GAS6/AXL), 3D1001, 3D1002, 3D185, 3D011, 3D1015, 3D197, 3D125, 3D124, 3D057, 3D059, and 3D062 across various stages of clinical and preclinical development for multiple indications. Founded in 2014, the company is headquartered in Qingdao, China.